Literature DB >> 23009110

Primary biliary cirrhosis: a multi-faced interactive disease involving genetics, environment and the immune response.

Raivo Uibo1, Kai Kisand, Chen-Yen Yang, M Eric Gershwin.   

Abstract

Primary biliary cirrhosis (PBC) is considered a model autoimmune disease based on several features, including the presence of a highly directed and very specific immune response to mitochondrial autoantigens, a female predominance, a targeted destruction of the biliary epithelium, and homogeneity between patients. It is essentially a chronic progressive cholestatic liver disease characterized by immune-mediated destruction of small- and medium-sized intrahepatic bile ducts. There is considerable variation in the incidence and prevalence of the disease between regions of the world, although such differences likely reflect not only a true disparity in disease but also differences in awareness; for example, in the United States, PBC is often detected in an asymptomatic stage based on multi-phasic clinical testing. There has been considerable progress at defining the immune response in this disease, including quantitation of autoreactive T cells against PDC-E2, the major mitochondrial autoantigen. The overwhelming data suggests that patients develop PBC based on a genetic predisposition and loss of tolerance to one or more environmental agents. In this review, we will present an updated overview of PBC and place it in the context of autoimmunity.
© 2012 The Authors APMIS © 2012 APMIS.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23009110     DOI: 10.1111/j.1600-0463.2012.02914.x

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  8 in total

1.  High frequency of antiphospholipid antibodies in primary biliary cirrhosis.

Authors:  Amani Mankaï; Wiem Manoubi; Mariam Ghozzi; Sarra Melayah; Wahiba Sakly; Ibtissem Ghedira
Journal:  J Clin Lab Anal       Date:  2014-03-28       Impact factor: 2.352

2.  Vitamin D in primary biliary cirrhosis, a plausible marker of advanced disease.

Authors:  Nancy Agmon-Levin; Ron Kopilov; Carlo Selmi; Udi Nussinovitch; María Sánchez-Castañón; Marcos López-Hoyos; Howie Amital; Shaye Kivity; Eric M Gershwin; Yehuda Shoenfeld
Journal:  Immunol Res       Date:  2015-02       Impact factor: 2.829

Review 3.  A contemporary perspective on the molecular characteristics of mitochondrial autoantigens and diagnosis in primary biliary cholangitis.

Authors:  Patrick S C Leung; Jinjung Choi; Guoxiang Yang; Elena Woo; Thomas P Kenny; M Eric Gershwin
Journal:  Expert Rev Mol Diagn       Date:  2016-03-30       Impact factor: 5.225

Review 4.  Autoantibodies in primary biliary cirrhosis: recent progress in research on the pathogenetic and clinical significance.

Authors:  Satoshi Yamagiwa; Hiroteru Kamimura; Masaaki Takamura; Yutaka Aoyagi
Journal:  World J Gastroenterol       Date:  2014-03-14       Impact factor: 5.742

5.  Predictors of liver failure in primary biliary cirrhosis.

Authors:  Pan Zhao; Wei-wei Liu; Jin-feng Li; Chun-ya Wang; Hao Wang; Jun Xu; Rui-fang Wang; Hao-zhen Yang; Cheng Jin; Zhen-man Wei
Journal:  Ups J Med Sci       Date:  2014-11-28       Impact factor: 2.384

Review 6.  Primary biliary cirrhosis is a generalized autoimmune epithelitis.

Authors:  Jun Gao; Liang Qiao; Bingyuan Wang
Journal:  Int J Mol Sci       Date:  2015-03-20       Impact factor: 5.923

7.  The Critical Role of Chemokine (C-C Motif) Receptor 2-Positive Monocytes in Autoimmune Cholangitis.

Authors:  Debby Reuveni; Yael Gore; Patrick S C Leung; Yael Lichter; Itay Moshkovits; Ayelet Kaminitz; Eli Brazowski; Eric Lefebvre; Pamela Vig; Chen Varol; Zamir Halpern; Oren Shibolet; Merrill Eric Gershwin; Ehud Zigmond
Journal:  Front Immunol       Date:  2018-08-15       Impact factor: 7.561

8.  A high bile acid environment promotes apoptosis and inhibits migration in pancreatic cancer.

Authors:  Shaopu Zhu; Kang Yang; Shiyi Yang; Li Zhang; Maoming Xiong; Jiawei Zhang; Bo Chen
Journal:  Bioengineered       Date:  2022-03       Impact factor: 3.269

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.